Welcome to our dedicated page for Verve Therapeutics news (Ticker: VERV), a resource for investors and traders seeking the latest updates and insights on Verve Therapeutics stock.
Verve Therapeutics was a clinical-stage company developing genetic medicines for cardiovascular disease before its completed acquisition by Eli Lilly and Company. Its public updates centered on in vivo base-editing programs such as VERVE-102, which targets PCSK9 in the liver to reduce LDL-C, along with clinical and regulatory disclosures, operating and financial results, and equity award activity under Nasdaq inducement-grant rules.
Company news also included investor-conference participation, material-agreement and shareholder-voting developments, governance matters, capital-structure disclosure, and risk-factor updates tied to its public-company status and acquisition process.
Verve Therapeutics has priced its initial public offering (IPO) at $19.00 per share, raising approximately $266.7 million before expenses. The offering consists of 14,035,789 shares, with an additional 2,105,368 shares available to underwriters. This IPO is scheduled to trade on the Nasdaq under the symbol VERV starting June 17, 2021, and is expected to close on June 21, 2021. J.P. Morgan, Jefferies, Guggenheim Securities, and William Blair serve as joint book-running managers for the offering.